Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Clinical Investigation
Additional Effects of Bosentan in Patients With Idiopathic Pulmonary Arterial Hypertension Already Treated With High-Dose Epoprostenol
Satoshi AkagiHiromi MatsubaraKatsumasa MiyajiEtsuko IkedaKazuhiro DanNaoto TokunagaKenichi HisamatsuMitsuru MunemasaYoshihisa FujimotoTohru Ohe
Author information

2008 Volume 72 Issue 7 Pages 1142-1146


Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose epoprostenol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6±43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99.6±43.4 to 82.8±31.3 ng · kg-1 · min-1, p<0.05). There was a significant decrease from the baseline value for systolic pulmonary artery pressure (80.1±19.3 to 66.8±16.5 mmHg, p<0.05). These effects were maintained for 1 year without progression of PAH in 6 patients whose condition had been stabilized at baseline. Conclusions The additional use of bosentan for IPAH patients whose condition has been stabilized by high-dose EPO is safe and effective. (Circ J 2008; 72: 1142 - 1146)

Content from these authors
Previous article Next article